Compositions containing histamine-H2-receptor antagonists at low dosage
AssigneeSmithKline Beecham Corporation
InventorAdrian F. Davis
Life of this patent
Estimating the term…
Abstract
Compositions for oral administration for the treatment of gastric disorders comprising histamine H.sub.2 -receptor antagonist and antacid, optionally buffered to promote local absorption of the H.sub.2 -receptor antagonist, wherein the quantity of H.sub.2 -receptor antagonist per unit dosage form is less than 25 mg.
Claims10
A pharmaceutical composition for treating gastric disorders, said composition comprising a histamine H.sub.2 -receptor antagonist and an antacid, wherein the composition is optimally buffered to confer a pH substantially equal to that of the pKa of the histamine H.sub.2 -receptor antagonist and promote local absorption of the H.sub.2 -receptor antagonist, characterized in that the dose of histamine H.sub.2 -receptor antagonist per unit dosage form is less than 25 mg, provided that the composition does not contain sodium polyacrylate.
A method of treating gastric disorders comprising orally administering to a sufferer an effective amount of a pharmaceutical composition, said composition comprising a histamine H.sub.2 -receptor antagonist and an antacid, wherein the composition is optimally buffered such that the equilibrium pH, the acid neutralizing capacity and the gastric residence time values confer a pH level substantially equal to that of the pKa of the histamine H.sub.2 -receptor antagonist, characterized in that the dose of histamine H.sub.2 -receptor antagonist per unit dosage form is less than 25 mg, provided that the composition does not contain sodium polyacrylate.
Dependencies are inferred from the claim text.